Michael Ison, MD MS
North Western University
H-index: 64
Asia-Bangladesh
Top articles of Michael Ison, MD MS
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons | Clinical Infectious Diseases | Michael G Ison Alberto Papi Eugene Athan Robert G Feldman Joanne M Langley | 2024/1/22 |
Integration of individualized and population-level molecular epidemiology data to model COVID-19 outcomes | Cell Reports Medicine | Ted Ling-Hu Lacy M Simons Taylor J Dean Estefany Rios-Guzman Matthew T Caputo | 2024/1/16 |
Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic | Nature Communications | Estefany Rios-Guzman Lacy M Simons Taylor J Dean Francesca Agnes Anna Pawlowski | 2024/4/20 |
Respiratory syncytial virus prefusion F protein vaccine is efficacious in older adults with underlying medical conditions | Clinical Infectious Diseases | Robert G Feldman Raffaele Antonelli-Incalzi Katie Steenackers Dong-Gun Lee Alberto Papi | 2024/1/15 |
Presentation, management, and outcomes of norovirus in adult and pediatric solid organ and hematopoietic stem cell transplant recipients: A multicenter, retrospective study | Transplant Infectious Disease | Michelle Callegari Lara A Danziger‐Isakov Anne Rose Daniel Kaul Kelly Shaffer | 2024/3/25 |
Physics-driven structural docking and protein language models accelerate antibody screening and design for broad-spectrum antiviral therapy | bioRxiv | Hannah Faisal Mubarak Wuwei Tan Andrew Daniel Hoffmann Juncheng Wei Lamiaa El-Shennawy | 2024 |
Delayed mortality among solid organ transplant recipients hospitalized for COVID-19 | Sarah Georgia Julie Steinbrink Barbara Alexander Emily Blumberg Brandy Haydel | 2022/2/25 | |
Efficacité d’un vaccin du virus respiratoire syncytial avec protéine F pré-fusion (RSVPreF3 OA) chez les adultes âgés avec maladies cardiorespiratoires pré-existantes | Revue des Maladies Respiratoires Actualités | A Gruber A Papi RG Feldman R Antonelli-Incalzi K Steenackers | 2024/1/1 |
Breakthrough SARS‐CoV‐2 infections among recipients of tixagevimab‐cilgavimab prophylaxis: A citywide real‐world effectiveness study | Transplant Infectious Disease | Frances R Lendacki Linda Li Graeme N Forrest Leirah Jordan Christy Zelinski | 2024/2 |
1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults≥ 60 Years of Age Persists for 2 RSV Seasons | Open Forum Infectious Diseases | Michael G Ison Alberto Papi Joanne M Langley Dong-Gun Lee Isabel Leroux-Roels | 2023/12 |
Evaluation of Immunocompetence and Biomarkers of Tolerance in Chimeric and Immunosuppression-free Kidney Allograft Recipients | Transplantation | Joseph R Leventhal John Galvin Michael G Ison Chris Yuhsuen Feng Ruchuang Ding | 2023/10/1 |
Altered RSV Epidemiology and Genetic Diversity Following the COVID-19 Pandemic | Research Square | Judd Hultquist Estefany Rios-Guzman Lacy Simons Taylor Dean Francesca Agnes | 2023/12/15 |
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE) | Open Forum Infectious Diseases | Michael G Ison Debra F Weinstein Marta Dobryanska Anna Holmes Anne-Marie Phelan | 2023/7 |
Quantity of SARS-CoV-2 RNA copies exhaled per minute during natural breathing over the course of COVID-19 infection (preprint) | Gregory Lane Guangyu Zhou Judd F Hultquist Lacy M Simons Ramon Lorenzo-Redondo | 2023 | |
A Respiratory Syncytial Virus (RSV) Prefusion F Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults≥ 60 Years of Age (YOA) | Pneumologie | M Ison A Papi J Langley D Lee I Leroux-Roels | 2023/3/9 |
920. A Phase 2 Multi-Center, Prospective, Randomized, Double-Blind Study to Assess the Clinical and Antiviral Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus … | Open Forum Infectious Diseases | Catherine-Audrey Boutin Michelle A Callegari Diana F Florescu Minh-Hong Nguyen Daniel Kaul | 2023/12 |
Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients | Clinical Infectious Diseases | Lora D Thomas Einas Batarseh Lubna Hamdan Zaid Haddadin Daniel Dulek | 2023/12/15 |
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study | The Oncologist | Peter G Doukas Frederique St. Pierre Reem Karmali Xinlei Mi Jennifer Boyer | 2023/10/1 |
Development of de novo donor‐specific antibodies in renal transplant recipients with BK viremia managed with immunosuppression reduction | Transplant Infectious Disease | Reut Hod‐Dvorai Ryan Lee Penn Muluhngwi Mariella Raijmakers Aneesha Shetty | 2023/2 |
MAJOR ARTICLE | Joseph E Levitt Haley Hedlin Sophie Duong Di Lu Justin Lee | 2023 |
Co-Authors
